Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.
The Editors welcome:
Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies
Drug Evaluations reviewing the clinical and pharmacological data on a particular drug
Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
《Expert Opinion On Investigational Drugs》是一本由TAYLOR & FRANCIS LTD出版商出版的专业医学期刊,该刊创刊于1994年,刊期Monthly,该刊已被国际权威数据库SCIE收录。在中科院最新升级版分区表中,该刊分区信息为大类学科:医学 2区,小类学科:药学 2区;在JCR(Journal Citation Reports)分区等级为Q1。该刊发文范围涵盖药学等领域,旨在及时、准确、全面地报道国内外药学工作者在该领域取得的最新研究成果、工作进展及学术动态、技术革新等,促进学术交流,鼓励学术创新。2021年影响因子为6.498,平均审稿速度较慢,6-12周。
大类学科 | 分区 | 小类学科 | 分区 | Top期刊 | 综述期刊 |
医学 | 2区 | PHARMACOLOGY & PHARMACY 药学 | 2区 | 否 | 是 |
JCR分区等级 | JCR所属学科 | 分区 | 影响因子 |
Q1 | PHARMACOLOGY & PHARMACY | Q1 | 6.498 |
影响因子 | h-index | Gold OA文章占比 | 研究类文章占比 | OA开放访问 | 平均审稿速度 |
6.498 | 94 | 10.13% | 38.14% | 未开放 | 较慢,6-12周 |